4.7 Review

Novel approaches for efficient in vivo fermentation production of noncoding RNAs

期刊

APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
卷 104, 期 5, 页码 1927-1937

出版社

SPRINGER
DOI: 10.1007/s00253-020-10350-3

关键词

Noncoding RNA; MicroRNA; siRNA; Bioengineering; Biotechnology

资金

  1. National Cancer Institute [R01CA225958]
  2. National Institute of General Medical Sciences [R01GM113888]
  3. National Institutes of Health

向作者/读者索取更多资源

Genome-derived noncoding RNAs (ncRNAs), including microRNAs (miRNAs), small interfering RNAs (siRNAs), and long noncoding RNAs (lncRNAs), play an essential role in the control of target gene expression underlying various cellular processes, and dysregulation of ncRNAs is involved in the pathogenesis and progression of various diseases in virtually all species including humans. Understanding ncRNA biology has opened new avenues to develop novel RNA-based therapeutics. Presently, ncRNA research and drug development is dominated by the use of ncRNA mimics that are synthesized chemically in vitro and supplemented with extensive and various types of artificial modifications and thus may not necessarily recapitulate the properties of natural RNAs generated and folded in living cells in vivo. Therefore, there are growing interests in developing novel technologies for in vivo production of RNA molecules. The two most recent major breakthroughs in achieving an efficient, large-scale, and cost-effective fermentation production of recombinant or bioengineered RNAs (e.g., tens of milligrams from 1 L of bacterial culture) are (1) using stable RNA carriers and (2) direct overexpression in RNase III-deficient bacteria, while other approaches offer a low yield (e.g., nano- to microgram scales per liter). In this article, we highlight these novel microbial fermentation-based technologies that have shifted the paradigm to the production of true biological ncRNA molecules for research and development.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

A Novel Bioengineered miR-127 Prodrug Suppresses the Growth and Metastatic Potential of Triple-Negative Breast Cancer Cells

Maxine Umeh-Garcia, Catalina Simion, Pui-Yan Ho, Neelu Batra, Anastasia L. Berg, Kermit L. Carraway, Aiming Yu, Colleen Sweeney

CANCER RESEARCH (2020)

Review Pharmacology & Pharmacy

RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges

Ai-Ming Yu, Young Hee Choi, Mei-Juan Tu

PHARMACOLOGICAL REVIEWS (2020)

Article Pharmacology & Pharmacy

Single bioengineered ncRNA molecule for dual-targeting toward the control of non-small cell lung cancer patient-derived xenograft tumor growth

Hannah Petrek, Pui Yan Ho, Neelu Batra, Mei-Juan Tu, Qianyu Zhang, Jing-Xin Qiu, Ai-Ming Yu

Summary: This study introduces a novel technology for dual-targeting of two miRNAs in NSCLC cells, showing greater efficacy in inhibiting cell growth and colony formation compared to using individual miRNAs alone. Additionally, a specific miRNA-loaded nanomedicine demonstrated the best effectiveness in controlling tumor growth in NSCLC patient-derived xenograft mouse models.

BIOCHEMICAL PHARMACOLOGY (2021)

Article Pharmacology & Pharmacy

A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine In Vivo Synergisms

Young Hee Choi, Chao Zhang, Zhenzhen Liu, Mei-Juan Tu, Ai-Xi Yu, Ai-Ming Yu

Summary: This study developed a novel pharmacokinetic (PK)-pharmacodynamic (PD) model for assessing combination treatment by considering contributions from individual drugs, and incorporated the combination index method to define in vivo synergism accurately. The research found that sorafenib contributed more to tumor growth inhibition compared to coadministered doxorubicin, explaining previously inexplicable clinical observations. This model and strategy will have broad applications in translational research for identifying optimal dosage combinations with stronger synergy to improve therapeutic outcomes.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2021)

Editorial Material Pharmacology & Pharmacy

RNA therapeutics: From biochemical pharmacology to technology development and clinical applications Preface

Baitang Ning, Ai-Ming Yu

BIOCHEMICAL PHARMACOLOGY (2021)

Article Oncology

Targeting Feedforward Loops Formed by Nuclear Receptor RORγ and Kinase PBK in mCRPC with Hyperactive AR Signaling

Xiong Zhang, Zenghong Huang, Junjian Wang, Zhao Ma, Joy Yang, Eva Corey, Christopher P. Evans, Ai-Ming Yu, Hong-Wu Chen

Summary: Prostate cancer is a common cancer in men with limited therapeutic options, but targeting drivers other than AR, such as RORgamma, may provide new treatment strategies. The study demonstrated that RORgamma antagonists effectively inhibit the growth of advanced prostate cancer tumors, suggesting a promising new approach for treating this aggressive disease.

CANCERS (2021)

Article Biochemistry & Molecular Biology

ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling

Chengfei Liu, Cameron M. Armstrong, Shu Ning, Joy C. Yang, Wei Lou, Alan P. Lombard, Jinge Zhao, Chun-Yi Wu, Aiming Yu, Christopher P. Evans, Clifford G. Tepper, Pui-kai Li, Allen C. Gao

Summary: The use of a novel AR/AR-V7 degrader ARVib effectively degrades AR/AR-V7 protein in prostate cancer cells and attenuates AR/AR-V7 downstream target gene expression. Mechanistically, ARVib degrades AR/AR-V7 protein through the ubiquitin-proteasome pathway mediated by HSP70/STUB1 machinery modulation, which inhibits resistant prostate tumor growth and improves enzalutamide treatment both in vitro and in vivo. These findings suggest that ARVib has potential as a therapy for resistant CRPC by targeting AR/AR-V7 degradation.

ONCOGENE (2021)

Article Pharmacology & Pharmacy

Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo

Linglong Deng, Hannah Petrek, Mei-Juan Tu, Neelu Batra, Ai-Xi Yu, Ai-Ming Yu

Summary: This study investigates the molecular and cellular mechanisms of miR-124-3p in controlling tumor metastasis by downregulating proteins critical for metastatic potential. The findings suggest that miR-124-3p therapy could inhibit cancer cell invasion and metastasis by disrupting cell structures and interactions.

ACTA PHARMACEUTICA SINICA B (2021)

Article Oncology

The Cationic Amphiphilic Drug Hexamethylene Amiloride Eradicates Bulk Breast Cancer Cells and Therapy-Resistant Subpopulations with Similar Efficiencies

Anastasia L. Berg, Ashley Rowson-Hodel, Michelle Hu, Michael Keeling, Hao Wu, Kacey VanderVorst, Jenny J. Chen, Jason Hatakeyama, Joseph Jilek, Courtney A. Dreyer, Madelyn R. Wheeler, Ai-Ming Yu, Yuanpei Li, Kermit L. Carraway

Summary: Preventing drug resistance in cancer stem cells is crucial for improving treatment outcomes in cancer patients. This study found that cationic amphiphilic drugs can effectively target therapy-resistant cancer stem cell populations by inducing cell death through a different mechanism. This discovery has the potential to improve treatment outcomes for breast cancer patients and reduce the risk of tumor recurrence and metastasis.

CANCERS (2022)

Review Pharmacology & Pharmacy

RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies

Gavin M. Traber, Ai-Ming Yu

Summary: RNA interference (RNAi) is a versatile method for regulating gene expression. Endogenous microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs) form RNA-induced silencing complexes to achieve gene regulation. RNAi-based drugs have been approved for clinical use and advancements in technology aim to improve their efficacy and safety. Chemical modifications and delivery platforms are being explored to enhance the structure, stability, and activity of RNA molecules. Novel biologic RNAi agents are also being developed for research purposes.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2023)

Article Oncology

Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment

Shu Ning, Chengfei Liu, Wei Lou, Joy C. Yang, Alan P. Lombard, Leandro S. D'Abronzo, Neelu Batra, Ai-Ming Yu, Amy R. Leslie, Masuda Sharifi, Christopher P. Evans, Allen C. Gao

Summary: Next-generation antiandrogen drugs improve survival and quality of life in advanced prostate cancer patients, but resistance to these drugs is not well understood. This study found that the Wnt5a/FZD2 signaling pathway plays a critical role in promoting enzalutamide resistance, and targeting this pathway could be a potential therapy for advanced prostate cancer.

MOLECULAR CANCER THERAPEUTICS (2022)

Review Pharmacology & Pharmacy

50th Anniversary Celebration Collection Special Section on Perspective on Drug Metabolism and Disposition, Part I-Minireview Recombinant Technologies Facilitate Drug Metabolism, Pharmacokinetics, and General Biomedical Research

Joseph M. Cronin, Ai -Ming Yu

Summary: The development of medications requires a thorough understanding of their pharmacokinetic and pharmacodynamic properties. The study of ADME gene products and their functions has been revolutionized by recombinant DNA technologies. These technologies enable the investigation of drug metabolism and disposition, as well as the study of posttranscriptional regulation of ADME genes.

DRUG METABOLISM AND DISPOSITION (2023)

Article Pharmacology & Pharmacy

Use of recombinant microRNAs as antimetabolites to inhibit human non-small cell lung cancer

Yixin Chen, Mei-Juan Tu, Fangwei Han, Zhenzhen Liu, Neelu Batra, Primo N. Lara, Hong -Wu Chen, Huichang Bi, Ai -Ming Yu

Summary: The research found that miR-22-3p, miR-9-5p, and miR-218-5p are antiproliferative miRNAs targeting non-small cell lung cancer (NSCLC) cells, and they inhibit folate metabolism and alter amino acid metabolism in NSCLC cells. In addition, the inhibition of glucose uptake by miR-22-3p and the reduction of serine biosynthesis from glucose by miR-9-5p and -218-5p were also confirmed. Recombinant miR-22-3p was more effective than miR-9-5p and -218-5p in inhibiting NSCLC cell respiration, glycolysis, and colony formation, without causing any toxicity.

ACTA PHARMACEUTICA SINICA B (2023)

Article Medicine, Research & Experimental

A novel miR-1291-ERR α-CPT1C axis modulates tumor cell proliferation, metabolism and tumorigenesis

Yixin Chen, Yanying Zhou, Fangwei Han, Yingyuan Zhao, Meijuan Tu, Yongtao Wang, Can Huang, Shicheng Fan, Panpan Chen, Xinpeng Yao, Lihuan Guan, Ai -Ming Yu, Frank J. Gonzalez, Min Huang, Huichang Bi

THERANOSTICS (2020)

Article Medicine, Research & Experimental

In vivo fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapy

Peng-Cheng Li, Mei-Juan Tu, Pui Yan Ho, Neelu Batra, Michelle M. L. Tran, Jing-Xin Qiu, Theodore Wun, Primo N. Lara, Xiang Hu, Ai-Xi Yu, Ai-Ming Yu

Summary: A novel platform for in vivo fermentation production of humanized recombinant ncRNA molecules was developed, demonstrating their important roles in cellular processes and anti-tumor activities. The technology represents a unique addition to conventional technologies for basic research and drug development.

THERANOSTICS (2021)

暂无数据